Company: AEMD
Filing Date: 2025-09-05
Form Type: 424B4
Source: 0001683168-25-006701
Chunk: 42

Company: AETHLON MEDICAL INC
Filing Date: 2025-09-05
Form: 424B4
Chunk 42
---
 relating to market size and growth and other data about our
industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.
In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate
are necessarily subject to a high degree of uncertainty and risk.

| 26 |

<div align='center'>USE OF PROCEEDS</div>

Inducement Offering

The Selling Securityholders
will be offering the shares of common stock underlying the Inducement Warrants being covered by this prospectus at prevailing market
prices or privately negotiated prices. We will not receive any proceeds from the sale of shares of common stock offered by the Selling
Securityholder under this prospectus. However, we will receive the proceeds of any cash exercise of the Inducement Warrants. If all of
the Inducement Warrants were exercised for cash, we would receive aggregate proceeds of approximately $4,634,500.Since the Inducement
Warrants are currently worth less than what an investor would pay per share, the Selling Securityholder is unlikely to exercise. Cash
proceeds associated with the exercise(s) of the Inducement Warrants, if any, are dependent on the Company’s stock price at the
time of exercise. If we receive proceeds, we currently intend to use the proceeds for general corporate purposes.

Company Offering

We estimate that the net
proceeds of the Company Offering will be approximately $3,903,750 based on the combined public offering price of $0.90 per share
and accompanying warrant after deducting the placement agent fees and estimated offering expenses payable by us, and excluding the proceeds,
if any, from the exercise of the warrants.

We currently intend to use the
net proceeds of the Company Offering for general corporate purposes, which will include research and development expenses, clinical trial
expenses, capital expenditures and working capital. We may also use a portion of the net proceeds from the Company Offering to in-license,
acquire, or invest in complementary businesses, technologies, products or assets. However, we have no current plans, commitments or obligations
to do so. Pending use of the net proceeds, we intend to invest the proceeds in a variety of capital preservation instruments, including short-term, investment-grade, interest-bearing instruments.

We cannot currently allocate
specific percentages of the net proceeds to us from the Company Offering that we may use for the purposes specified above and our management
will have broad